| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Regular Articles |
Departments of 1 Experimental Radiation Oncology, 2 Molecular Genetics, and 3 Biomathematics, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, and 4 Cancer Biology Program, Graduate School of Biomedical Sciences, University of Texas Health Science Center, Houston, Texas
The deregulated expression of cyclin E as measured by the overexpression of its low molecular weight (LMW) isoforms is a powerful predictor of poor outcome in patients with breast cancer. The mechanism by which these LMW forms give tumor cells a growth advantage is not known and is the subject of this article. In this article, we provide the pathobiological mechanisms of how these LMW forms are involved in disease progression. Specifically, we show that overexpression of the LMW forms of cyclin E but not the full-length form in MCF-7 results in (a) their hyperactivity because of increased affinity for cdk2 and resistance to inhibition by the cyclin-dependent kinase inhibitors p21 and p27, (b) resistance to the growth inhibiting effects of antiestrogens, and (c) chromosomal instability. Lastly, tumors from breast cancer patients overexpressing the LMW forms of cyclin E are polyploid in nature and are resistant to endocrine therapy. Collectively, the biochemical and functional differences between the full-length and the LMW isoforms of cyclin E provide a molecular mechanism for the poor clinical outcome observed in breast cancer patients harboring tumors expressing high levels of the LMW forms of cyclin E. These properties of the LMW forms cyclin E suggest that they are not just surrogate markers of poor outcome but bona fide mediators of aggressive disease and potential therapeutic targets for patients whose tumors overexpress these forms.
This article has been cited by other articles:
|
|
 |
|
  P Berglund, M Stighall, K Jirstrom, L Ryden, M Ferno, B Nordenskjold, and G Landberg Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern J. Clin. Pathol., February 1, 2008; 61(2): 184 - 191. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Bedrosian, C. Lee, S. L. Tucker, S. L. Palla, K. Lu, and K. Keyomarsi Cyclin E Associated Kinase Activity Predicts Response to Platinum-Based Chemotherapy Clin. Cancer Res., August 15, 2007; 13(16): 4800 - 4806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Akli, C. S. Van Pelt, T. Bui, A. S. Multani, S. Chang, D. Johnson, S. Tucker, and K. Keyomarsi Overexpression of the Low Molecular Weight Cyclin E in Transgenic Mice Induces Metastatic Mammary Carcinomas through the Disruption of the ARF-p53 Pathway Cancer Res., August 1, 2007; 67(15): 7212 - 7222. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. N. Span, P. H. de Mulder, and F. C. G. J. Sweep Re: p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy J Natl Cancer Inst, May 2, 2007; 99(9): 738 - 738. [Full Text] [PDF]
|
|
|
|
|
|
P. L. Porter, W. E. Barlow, I-T. Yeh, M. G. Lin, X. P. Yuan, E. Donato, G. W. Sledge, C. L. Shapiro, J. N. Ingle, C. M. Haskell, et al. p27Kip1 and Cyclin E Expression and Breast Cancer Survival After Treatment With Adjuvant Chemotherapy J Natl Cancer Inst, December 6, 2006; 98(23): 1723 - 1731. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. Spruck, D. Sun, H. Fiegl, C. Marth, E. Mueller-Holzner, G. Goebel, M. Widschwendter, and S. I. Reed Detection of low molecular weight derivatives of cyclin e1 is a function of cyclin e1 protein levels in breast cancer. Cancer Res., July 15, 2006; 66(14): 7355 - 7360. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C.-C. Yen, Y.-H. Huang, C.-Y. Liao, C.-J. Liao, W.-L. Cheng, W.-J. Chen, and K.-H. Lin Mediation of the inhibitory effect of thyroid hormone on proliferation of hepatoma cells by transforming growth factor-beta J. Mol. Endocrinol., February 1, 2006; 36(1): 9 - 21. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Yeh, B. O. Lew, and A. R. Means The Loss of PIN1 Deregulates Cyclin E and Sensitizes Mouse Embryo Fibroblasts to Genomic Instability J. Biol. Chem., January 6, 2006; 281(1): 241 - 251. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Libertini, B. S. Robinson, N. K. Dhillon, D. Glick, M. George, S. Dandekar, J. P. Gregg, E. Sawai, and M. Mudryj Cyclin E Both Regulates and Is Regulated by Calpain 2, a Protease Associated with Metastatic Breast Cancer Phenotype Cancer Res., December 1, 2005; 65(23): 10700 - 10708. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Hu, S. Washington, M. F. Verderame, and A. Manni Interaction between Polyamines and the Mitogen-Activated Protein Kinase Pathway in the Regulation of Cell Cycle Variables in Breast Cancer Cells Cancer Res., December 1, 2005; 65(23): 11026 - 11033. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Colozza, E. Azambuja, F. Cardoso, C. Sotiriou, D. Larsimont, and M. J. Piccart Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now? Ann. Onc., November 1, 2005; 16(11): 1723 - 1739. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. L. Grimm, A. Contreras, M.-H. Barcellos-Hoff, and J. M. Rosen Cell Cycle Defects Contribute to a Block in Hormone-induced Mammary Gland Proliferation in CCAAT/Enhancer-binding Protein (C/EBP{beta})-null Mice J. Biol. Chem., October 28, 2005; 280(43): 36301 - 36309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Eder, X. Sui, D. G. Rosen, L. K Nolden, K. W. Cheng, J. P. Lahad, M. Kango-Singh, K. H. Lu, C. L. Warneke, E. N. Atkinson, et al. Atypical PKC{iota} contributes to poor prognosis through loss of apical-basal polarity and Cyclin E overexpression in ovarian cancer PNAS, August 30, 2005; 102(35): 12519 - 12524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. J Butt, C. M McNeil, E. A Musgrove, and R. L Sutherland Downstream targets of growth factor and oestrogen signalling and endocrine resistance: the potential roles of c-Myc, cyclin D1 and cyclin E Endocr. Relat. Cancer, July 1, 2005; 12(Supplement_1): S47 - S59. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Lu, K. A. Seta, and D. E. Millhorn Novel Role for Cyclin-dependent Kinase 2 in Neuregulin-induced Acetylcholine Receptor {epsilon} Subunit Expression in Differentiated Myotubes J. Biol. Chem., June 10, 2005; 280(23): 21731 - 21738. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Mukherjee and S. E. Conrad c-Myc Suppresses p21WAF1/CIP1 Expression during Estrogen Signaling and Antiestrogen Resistance in Human Breast Cancer Cells J. Biol. Chem., May 6, 2005; 280(18): 17617 - 17625. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. O. Chappuis, E. Donato, J. R. Goffin, N. Wong, L. R. Begin, L. R. Kapusta, J.-S. Brunet, P. Porter, and W. D. Foulkes Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment Ann. Onc., May 1, 2005; 16(5): 735 - 742. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wingate, N. Zhang, M. J. McGarhen, I. Bedrosian, J. W. Harper, and K. Keyomarsi The Tumor-specific Hyperactive Forms of Cyclin E Are Resistant to Inhibition by p21 and p27 J. Biol. Chem., April 15, 2005; 280(15): 15148 - 15157. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Bales, L. Mills, N. Milam, M. McGahren-Murray, D. Bandyopadhyay, D. Chen, J. A. Reed, N. Timchenko, J. J. van den Oord, M. Bar-Eli, et al. The Low Molecular Weight Cyclin E Isoforms Augment Angiogenesis and Metastasis of Human Melanoma Cells In vivo Cancer Res., February 1, 2005; 65(3): 692 - 697. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
